| Literature DB >> 25800544 |
Sebastian A Mikolajczak1, Ashley M Vaughan2, Niwat Kangwanrangsan3, Wanlapa Roobsoong4, Matthew Fishbaugher2, Narathatai Yimamnuaychok4, Nastaran Rezakhani2, Viswanathan Lakshmanan2, Naresh Singh5, Alexis Kaushansky2, Nelly Camargo2, Michael Baldwin2, Scott E Lindner6, John H Adams5, Jetsumon Sattabongkot, Jetsumon Prachumsri4, Stefan H I Kappe7.
Abstract
Plasmodium vivax malaria is characterized by periodic relapses of symptomatic blood stage parasite infections likely initiated by activation of dormant liver stage parasites-hypnozoites. The lack of tractable P. vivax animal models constitutes an obstacle in examining P. vivax liver stage infection and drug efficacy. To overcome this obstacle, we have used human liver-chimeric (huHep) FRG KO mice as a model for P. vivax infection. FRG KO huHep mice support P. vivax sporozoite infection, liver stage development, and hypnozoite formation. We show complete P. vivax liver stage development, including maturation into infectious exo-erythrocytic merozoites as well as the formation and persistence of hypnozoites. Prophylaxis or treatment with the antimalarial primaquine can prevent and eliminate liver stage infection, respectively. Thus, P. vivax-infected FRG KO huHep mice are a model to investigate liver stage development and dormancy and may facilitate the discovery of drugs targeting relapsing malaria.Entities:
Mesh：
Substances：
Year: 2015 PMID： 25800544 PMCID： PMC5299596 DOI： 10.1016/j.chom.2015.02.011
Source DB: PubMed Journal: Cell Host Microbe ISSN： 1931-3128 Impact factor: 21.023